These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 18781673)

  • 1. Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy.
    Grace AA
    Mov Disord; 2008; 23 Suppl 3():S560-9. PubMed ID: 18781673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synaptic dysfunction in Parkinson's disease.
    Bagetta V; Ghiglieri V; Sgobio C; Calabresi P; Picconi B
    Biochem Soc Trans; 2010 Apr; 38(2):493-7. PubMed ID: 20298209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myths and realities of continuous dopaminergic stimulation.
    Pirtošek Z
    Psychiatr Danub; 2011 Mar; 23(1):80-3. PubMed ID: 21448103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Thoughts on the neurobiological aspects of Parkinson syndrome].
    Sommer H
    Psychiatr Neurol Med Psychol (Leipz); 1986 Feb; 38(2):86-90. PubMed ID: 3010357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease.
    Obeso JA; Rodríguez-Oroz MC; Benitez-Temino B; Blesa FJ; Guridi J; Marin C; Rodriguez M
    Mov Disord; 2008; 23 Suppl 3():S548-59. PubMed ID: 18781672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GABA receptor agonists and extrapyramidal motor function: therapeutic implications for Parkinson's disease.
    Bartholini G; Scatton B; Zivkovic B; Lloyd KG
    Adv Neurol; 1987; 45():79-83. PubMed ID: 3030072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of catecholamines in regulating motor functions (review)].
    Barkhatova VP
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(7):1068-74. PubMed ID: 2863909
    [No Abstract]   [Full Text] [Related]  

  • 11. Synaptic plasticity, dopamine and Parkinson's disease: one step ahead.
    Calabresi P; Mercuri NB; Di Filippo M
    Brain; 2009 Feb; 132(Pt 2):285-7. PubMed ID: 19168452
    [No Abstract]   [Full Text] [Related]  

  • 12. Continuous dopaminergic stimulation: clinical aspects and experimental bases.
    Rodriguez-Oroz MC; Marin C; de Fabregues O
    Neurologist; 2011 Nov; 17(6 Suppl 1):S30-7. PubMed ID: 22045323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nondopaminergic mechanisms in levodopa-induced dyskinesia.
    Brotchie JM
    Mov Disord; 2005 Aug; 20(8):919-31. PubMed ID: 16007614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissociating the cognitive effects of levodopa versus dopamine agonists in a neurocomputational model of learning in Parkinson's disease.
    Moustafa AA; Herzallah MM; Gluck MA
    Neurodegener Dis; 2013; 11(2):102-11. PubMed ID: 23128796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine and the regulation of cognition and attention.
    Nieoullon A
    Prog Neurobiol; 2002 May; 67(1):53-83. PubMed ID: 12126656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease.
    Schapira AH
    Neurology; 2009 Feb; 72(7 Suppl):S44-50. PubMed ID: 19221314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH; Chuang R; Brotchie JM
    Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular principles underlying normal and pathological activity in the subthalamic nucleus.
    Bevan MD; Atherton JF; Baufreton J
    Curr Opin Neurobiol; 2006 Dec; 16(6):621-8. PubMed ID: 17084618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
    Jenner P
    Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.